Gap junctions and hemichannels composed of connexins: potential therapeutic targets for neurodegenerative diseases
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Microglia are macrophage-like resident immune cells that contribute to the maintenance of homeostasis in the central nervous system (CNS). Abnormal activation of microglia can cause damage in the CNS, and accumulation of activated microglia is a characteristic pathological observation in neurologic conditions such as trauma, stroke, inflammation, epilepsy, and neurodegenerative diseases. Activated microglia secrete high levels of glutamate, which damages CNS cells and has been implicated as a major cause of neurodegeneration in these conditions. Glutamate-receptor blockers and microglia inhibitors (e.g., minocycline) have been examined as therapeutic candidates for several neurodegenerative diseases; however, these compounds exerted little therapeutic benefit because they either perturbed physiological glutamate signals or suppressed the actions of protective microglia. The ideal therapeutic approach would hamper the deleterious roles of activated microglia without diminishing their protective effects. We recently found that abnormally activated microglia secrete glutamate via gap-junction hemichannels on the cell surface. Moreover, administration of gap-junction inhibitors significantly suppressed excessive microglial glutamate release and improved disease symptoms in animal models of neurologic conditions such as stroke, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Recent evidence also suggests that neuronal and glial communication via gap junctions amplifies neuroinflammation and neurodegeneration. Elucidation of the precise pathologic roles of gap junctions and hemichannels may lead to a novel therapeutic strategies that can slow and halt the progression of neurodegenerative diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528 · cited 1×
“…recently proposed hypothesis suggests, by analogy to macrophage activation, that activated microglia comprise two subpopulations, the neurotoxic (M1) and neuroprotective (M2) species (Mantovani et al., 2002; Henkel et al., 2009; Boche et al., 2013); however, this hypothesis is still open to debate.”
Microglia: a sensor for pathological events in the CNS
Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · cited 2×
“CELLULAR NEUROSCIENCE REVIEW ARTICLE published: 02 September 2014 doi: 10.3389/fncel.2014.00189 Gap junctions and hemichannels composed of connexins: potential therapeutic targets for neurodegenerative diseases”
InfluentialMicroglia-mediated neurotoxicity: uncovering the molecular mechanisms
Block, M. L., Zecca, L., & Hong, J.-S. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2038 · Cited by 4,110 · cited 3×
“…also enhance microglial neurotoxic effects by producing neurotoxic factors such as cytokines/chemokines, nucleic acids, excitatory amino acids, reactive oxygen species (ROS), and proteases (Kempermann and Neumann, 2003; Takeuchi et al., 2005, 2006; Kawanokuchi et al., 2006; Block et al., 2007).”
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
ATP mediates rapid microglial response to local brain injury in vivo
Davalos, D., Grutzendler, J., Yang, G., Kim, J. V., Zuo, Y., Jung, S., Littman, D. R., Dustin, M. L., & Gan, W.-B. (2005) · Nature Neuroscience · doi:10.1038/nn1472 · Cited by 3,913 · cited 1×
“Under healthy physiological conditions, microglia persist in a quiescent state with ramified morphology (resting microglia) and survey the environment of the CNS (Davalos et al., 2005; Nimmerjahn et al., 2005).”
Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain
Lawson, L. J., Perry, V. H., Dri, P., & Gordon, S. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90229-w · Cited by 2,045 · cited 1×
“Microglia are predominantly observed in gray matter, especially in the olfactory bulb, hippocampus, basal ganglia, and substantia nigra (Lawson et al., 1990).”
Kamata, H., Honda, S.-I., Maeda, S., Chang, L., Hirata, H., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2004.12.041 · Cited by 1,792
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Ziv, Y., Ron, N., Butovsky, O., Landa, G., Sudai, E., Greenberg, N., Cohen, H., Kipnis, J., & Schwartz, M. (2006) · Nature Neuroscience · doi:10.1038/nn1629 · Cited by 1,209
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183 · cited 1×
“At least in pathological conditions, deleterious microglial activation is probably involved in the progression of various neurological disorders (Yrjanheikki et al., 1998; Wu et al., 2002; Zhu et al., 2002; Stirling et al., 2004; Boillee et al., 2006; Seabrook et al., 2006).”
Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis
Yamanaka, K., Chun, S. J., Boillee, S., Fujimori-Tonou, N., Yamashita, H., Gutmann, D. H., Takahashi, R., Misawa, H., & Cleveland, D. W. (2008) · Nature Neuroscience · doi:10.1038/nn2047 · Cited by 1,140 · cited 1×
“Other studies have shown that microglia and astrocytes are determinants of disease progression in ALS (the non-autonomous neuronal death hypothesis) (Boillee et al., 2006; Yamanaka et al., 2008).”
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“…a characteristic pathological feature in many neurologic conditions such as trauma, stroke, inflammation, epilepsy, and neurodegenerative diseases (Cagnin et al., 2001; Eikelenboom et al., 2002; McGeer and McGeer, 2002; Nelson et al., 2002; Orr et al., 2002; Bruijn et al., 2004; Pavese et al.,…”
Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 1×
“At least in pathological conditions, deleterious microglial activation is probably involved in the progression of various neurological disorders (Yrjanheikki et al., 1998; Wu et al., 2002; Zhu et al., 2002; Stirling et al., 2004; Boillee et al., 2006; Seabrook et al., 2006).”
Microglia Promote the Death of Developing Purkinje Cells
Marı́n-Teva, J. L., Dusart, I., Colin, C., Gervais, A., van Rooijen, N., & Mallat, M. (2004) · Neuron · doi:10.1016/s0896-6273(04)00069-8 · Cited by 757
Takeuchi, H., Jin, S., Wang, J., Zhang, G., Kawanokuchi, J., Kuno, R., Sonobe, Y., Mizuno, T., & Suzumura, A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600504200 · Cited by 749 · cited 9×
“Recent studies have revealed the precise mechanism of glutamate production by activated microglia (Takeuchi et al., 2005, 2006) (Figure 1).”
InfluentialSelf-citationScavenger receptor-mediated adhesion of microglia to β-amyloid fibrils
Khoury, J. E., Hickman, S. E., Thomas, C. A., Cao, L., Silverstein, S. C., & Loike, J. D. (1996) · Nature · doi:10.1038/382716a0 · Cited by 727 · cited 1×
“TLRs and scavenger receptors may contribute to diminishing neurotoxicity by sequestering neurotoxic substances such as amyloid β (El Khoury et al., 1996; Coraci et al., 2002; Bamberger et al., 2003; Liu et al., 2005); however, signals downstream of these receptors also enhance microglial neurotoxic…”
Role of Microglia in Central Nervous System Infections
Rock, R. B., Gekker, G., Hu, S., Sheng, W. S., Cheeran, M., Lokensgard, J. R., & Peterson, P. K. (2004) · Clinical Microbiology Reviews · doi:10.1128/cmr.17.4.942-964.2004 · Cited by 723 · cited 1×
“…as Fc receptor, CD11b, CD11c, CD14, major histocompatibility complex (MHC) molecules, Toll-like receptors (TLRs), scavenger receptors, and cytokine/chemokine receptors, and they can act as both antigen-presenting cells and immunological effector cells (Suzumura et al., 1987; Rock et al., 2004).”
Impaired Electrical Signaling Disrupts Gamma Frequency Oscillations in Connexin 36-Deficient Mice
Hormuzdi, S. G., Pais, I., LeBeau, F. E. N., Towers, S. K., Rozov, A., Buhl, E. H., Whittington, M. A., & Monyer, H. (2001) · Neuron · doi:10.1016/s0896-6273(01)00387-7 · Cited by 522 · cited 1×
“Neuronal gap junctions composed of Cx36 and Cx45 are thought to be homomeric and homotypic (AlUbaidi et al., 2000; Teubner et al., 2001), and these junctions are important for formation of electrical synapses (Deans et al., 2001; Hormuzdi et al., 2001).”
A Cell Surface Receptor Complex for Fibrillar β-Amyloid Mediates Microglial Activation
Bamberger, M. E., Harris, M. E., McDonald, D. R., Husemann, J., & Landreth, G. E. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02665.2003 · Cited by 501
Inflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470 · cited 1×
“…characteristic pathological feature in many neurologic conditions such as trauma, stroke, inflammation, epilepsy, and neurodegenerative diseases (Cagnin et al., 2001; Eikelenboom et al., 2002; McGeer and McGeer, 2002; Nelson et al., 2002; Orr et al., 2002; Bruijn et al., 2004; Pavese et al., 2006).”
Microglial activation correlates with severity in Huntington disease: A clinical and PET study
Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P. (2006) · Neurology · doi:10.1212/01.wnl.0000222734.56412.17 · Cited by 462 · cited 2×
“CELLULAR NEUROSCIENCE REVIEW ARTICLE published: 02 September 2014 doi: 10.3389/fncel.2014.00189 Gap junctions and hemichannels composed of connexins: potential therapeutic targets for neurodegenerative diseases”
InfluentialBrain microglia constitutively express β-2 integrins
Akiyama, H., & McGeer, P. L. (1990) · Journal of Neuroimmunology · doi:10.1016/0165-5728(90)90055-r · Cited by 430 · cited 1×
“In fact, expression levels of TLRs and scavenger receptors are upregulated in a variety of neurologic diseases (Akiyama and McGeer, 1990; Grewal et al., 1997; El Khoury et al., 1998; Bsibsi et al., 2002; Cho et al., 2005; Carpentier et al., 2008).”
Coraci, I. S., Husemann, J., Berman, J. W., Hulette, C., Dufour, J. H., Campanella, G. K., Luster, A. D., Silverstein, S. C., & El Khoury, J. B. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64354-4 · Cited by 398 · cited 1×
“…and scavenger receptors may contribute to diminishing neurotoxicity by sequestering neurotoxic substances such as amyloid β (El Khoury et al., 1996; Coraci et al., 2002; Bamberger et al., 2003; Liu et al., 2005); however, signals downstream of these receptors also enhance microglial neurotoxic…”
Jimenez, S., Baglietto-Vargas, D., Caballero, C., Moreno-Gonzalez, I., Torres, M., Sanchez-Varo, R., Ruano, D., Vizuete, M., Gutierrez, A., & Vitorica, J. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3024-08.2008 · Cited by 383 · cited 1×
“Therefore, whether activated microglia exert a neurotoxic or a neuroprotective effect may depend on their environment, the spatiotemporal distribution of the microglia themselves, and the type and magnitude of stimuli (Jimenez et al., 2008; Wu et al., 2008; Nakanishi and Wu, 2009; Sawada, 2009).”
Microglia in ALS: The Good, The Bad, and The Resting
Henkel, J. S., Beers, D. R., Zhao, W., & Appel, S. H. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9171-5 · Cited by 353 · cited 1×
“…recently proposed hypothesis suggests, by analogy to macrophage activation, that activated microglia comprise two subpopulations, the neurotoxic (M1) and neuroprotective (M2) species (Mantovani et al., 2002; Henkel et al., 2009; Boche et al., 2013); however, this hypothesis is still open to debate.”
Richard, K. L., Filali, M., Préfontaine, P., & Rivest, S. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1146-08.2008 · Cited by 298 · cited 1×
“…by clearance of cellular debris and toxic substances (Upender and Naegele, 1999; Marin-Teva et al., 2004; Iribarren et al., 2005; Simard et al., 2006; Richard et al., 2008), and guidance of stem-cell migration in neuronal repair and neurogenesis (Aarum et al., 2003; Ziv et al., 2006a,b).”
Takeuchi, H., Mizuno, T., Zhang, G., Wang, J., Kawanokuchi, J., Kuno, R., & Suzumura, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413863200 · Cited by 285 · cited 5×
“Recent studies have revealed the precise mechanism of glutamate production by activated microglia (Takeuchi et al., 2005, 2006) (Figure 1).”
InfluentialSelf-citationZiv, Y., Avidan, H., Pluchino, S., Martino, G., & Schwartz, M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603747103 · Cited by 285
Functional and morphological changes induced by transient in vivo ischemia
Hori, N., & Carpenter, D. O. (1994) · Experimental Neurology · doi:10.1006/exnr.1994.1170 · Cited by 161
Iribarren, P., Chen, K., Hu, J., Gong, W., Cho, E. H., Lockert, S., Uranchimeg, B., & Wang, J. M. (2005) · The FASEB Journal · doi:10.1096/fj.05-4578fje · Cited by 92
Lutz, S. E., Raine, C. S., & Brosnan, C. F. (2012) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2012.01.007 · Cited by 30
Cited by
Inflammation, glutamate, and glia: a trio of trouble in mood disorders
Haroon, E., Miller, A. H., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.199 · Cited by 584
Liang, Z., Wang, X., Hao, Y., Qiu, L., Lou, Y., Zhang, Y., Ma, D., & Feng, J. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00703 · Cited by 84
Gliotransmitters and cytokines in the control of blood-brain barrier permeability
Osipova, E. D., Semyachkina-Glushkovskaya, O. V., Morgun, A. V., Pisareva, N. V., Malinovskaya, N. A., Boitsova, E. B., Pozhilenkova, E. A., Belova, O. A., Salmin, V. V., Taranushenko, T. E., et al. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0092 · Cited by 72
Wang, Q., Lu, M., Zhu, X., Gu, X., Zhang, T., Xia, C., Yang, L., Xu, Y., & Zhou, M. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113412 · Cited by 52
Okada, M., Fukuyama, K., Shiroyama, T., & Ueda, Y. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111462 · Cited by 28
Metadata
- Authors
- Takeuchi, H., & Suzumura, A.
- Venue
- Frontiers in Cellular Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2014-09-02
- Volume
- 8
- Pages
- 189-189
- ISSN
- 1662-5102 (ISSN-L)
- OpenAlex
- W2017079337
- Cited by
- 121
- References
- 32
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.